Downstream processing of lentiviral vectors: Releasing bottlenecks

Human Gene Therapy Methods

Volumn 23, Issue 4, 2012, Pages 255-263

  Bandeira, Vanessa ^a   Peixoto, Cristina ^a   Rodrigues, Ana F ^a,b   Cruz, Pedro E ^a,d   Alves, Paula M ^a,b   Coroadinha, Ana S ^a,b   Carrondo, Manuel J T ^a,c  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d ECBio RandD in Biotechnology SA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIETHYLAMINOETHANOL; LENTIVIRUS VECTOR; VIRUS DNA; DEOXYRIBONUCLEASE; RIBONUCLEASE; SERRATIA MARCESCENS NUCLEASE;

ANION EXCHANGE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; DNA CONTENT; DOWNSTREAM PROCESSING; FREEZE THAWING; MEMBRANE TECHNOLOGY; MICROFILTRATION; NONHUMAN; PRIORITY JOURNAL; SCALE UP; SUPERNATANT; ULTRAFILTRATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CHARACTERIZATION; VIRUS PURIFICATION; CELL STRAIN HEK293; CENTRIFUGATION; GEL CHROMATOGRAPHY; GENE VECTOR; GENETICS; HUMAN; ION EXCHANGE CHROMATOGRAPHY; ISOLATION AND PURIFICATION; LENTIVIRINAE; METABOLISM;

CENTRIFUGATION; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; ENDODEOXYRIBONUCLEASES; ENDORIBONUCLEASES; GENETIC VECTORS; HEK293 CELLS; HUMANS; LENTIVIRUS;

EID: 84872231059     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.059     Document Type: Article

References (39)

1. Baekelandt, V., Eggermont, K., Michiels, M., et al. (2003). Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene. Ther. 10, 1933-1940. (Pubitemid 37337069)
2. Barut, M., Podgornik, A., Brne, P., et al. (2005). Convective interaction media short monolithic columns: enabling chromatographic supports for the separation and purification of large biomolecules. J. Sep. Sci. 28, 1876-1892. (Pubitemid 41614722)
3. Beer, C., Meyer, A., Muller, K., et al. (2003). The temperature stability of mouse retroviruses depends on the cholesterol levels of viral lipid shell and cellular plasma membrane. Virology 308, 137-146. (Pubitemid 36428972)
4. Carmo, M., Faria, T.Q., Falk, H., et al. (2006). Relationship between retroviral vector membrane and vector stability. J. Gen. Virol. 87, 1349-1356.
5. Carmo, M., Panet, A., Carrondo, M.J., et al. (2008). From retroviral vector production to gene transfer: spontaneous inactivation is caused by loss of reverse transcription capacity. J. Gene Med. 10, 383-391. (Pubitemid 351517094)
6. Carmo, M., Dias, J.D., Panet, A., et al. (2009). Thermosensitivity of the reverse transcription process as an inactivation mechanism of lentiviral vectors. Hum. Gene Ther. 20, 1168-1176.
7. Chen, J., Reeves, L., Sanburn, N., et al. (2001). Packaging cell line DNA contamination of vector supernatants: implication for laboratory and clinical research. Virology 282, 186-197. (Pubitemid 32881786)
8. Coroadinha, A.S., Ribeiro, J., Roldã o, A., et al. (2006a). Effect of medium sugar source on the production of retroviral vectors for gene therapy. Biotechnol. Bioeng. 94, 24-36. (Pubitemid 43723196)
9. Coroadinha, A.S., Silva, A.C., Pires, E., et al. (2006b). Effect of osmotic pressure on the production of retroviral vectors: Enhancement in vector stability. Biotechnol. Bioeng 94, 322-329. (Pubitemid 43799530)
10. Couture, L. (2008). Vector production in support of early clinical trials. Presented at the 11th annual ASGT Meeting, Boston.
11. Dupont, F. (2008). Large scale manufacturing of a lentiviral vector (ProSavin-) for phase I/II clinical trial. Presented at the CONSERT Labcourse, Evry, France.
12. Eglon, M.N., Duffy, A.M., O'Brien, T., et al. (2009). Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography. J. Gene Med. 11, 978-989.
13. Food and Drug Administration (2010). Guidance for Industry- Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications Available at www.fda.gov/downloads/biologicsbloodvaccines/guidance complianceregulatoryinformation/guidances/vaccines/ucm 202439.pdf (accessed April 2012).
14. Gagnon, P. (2010). Monoliths open the door to key growth sectors. BioProcess International 8, 20-23.
15. Gene Therapy Clinical Trials (2012). Available at www.wiley .co.uk/genmed/clinical (accessed June 2012).
16. Geraerts, M., Michiels, M., Baekelandt, V., et al. (2005). Upscaling of lentiviral vector production by tangential flow filtration. J. Gene Med. 7, 1299-1310. (Pubitemid 41555436)
17. Higashikawa, F., and Chang, L. (2001). Kinetic analyses of stability of simple and complex retroviral vectors. Virology 280, 124-131. (Pubitemid 34158058)
18. Ikeda, Y., Takeuchi, Y., Martin, F., et al. (2003). Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 21, 569-572. (Pubitemid 36532025)
19. Janning, P., Schrader, W., and Linscheid, M. (1994). A new mass spectrometric approach to detect modifications in DNA. Rapid Commun. Mass Spectrom. 8, 1035-1040.
20. Jungbauer, A., and Hahn, R. (2008). Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies. J. Chromatogr. A 1184, 62-79.
21. Lesch, H.P., Laitinen, A., Peixoto, C., et al. (2011) Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther. 18, 531-538.
22. Merten, O.W., Charrier, S., Laroudie, N., et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343-356.
23. Morenweiser, R. (2005). Downstream processing of viral vectors and vaccines. Gene Ther. 12, S103-S110. (Pubitemid 41541759)
24. Naldini, L., Blomer, U., Gage, F.H., et al. (1996a). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 93, 11382-11388. (Pubitemid 26347130)
25. Naldini, L., Blomer, U., Gallay, P., et al. (1996b). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267. (Pubitemid 26119138)
26. Podgornik, A., and Strancar, A. (2005). Convective Interaction Media-(CIM)-short layer monolithic chromatographic stationary phases. Biotechnol. Annu. Rev., 281-333.
27. Reeves, L., and Cornetta, K. (2000). Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther. 7, 1993-1998. (Pubitemid 32036764)
28. Rodrigues, T., Carvalho, A., Roldao, A., et al. (2006). Screening anion-exchange chromatographic matrices for isolation of onco-retroviral vectors. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 837, 59-68. (Pubitemid 43783316)
29. Rodrigues, T., Carrondo, M.J., Alves, P.M., et al. (2007a). Purification of retroviral vectors for clinical application: biological implications and technological challenges. J. Biotechnol. 127, 520-541. (Pubitemid 44827399)
30. Rodrigues, T., Carvalho, A., Carmo, M., et al. (2007b). Scaleable purification process for gene therapy retroviral vectors. J. Gene Med. 9, 233-243. (Pubitemid 46746314)
31. Sastry, L., Xu, Y., Cooper, R., et al. (2004). Evaluation of plasmid DNA removal from lentiviral vectors by Benzonase treatment. Hum. Gene Ther. 15, 221-226. (Pubitemid 38210536)
32. Schambach, A., and Baum, C. (2008). Clinical application of lentiviral vectors-concepts and practice. Curr. Gene Ther. 8, 474-482.
33. Schweizer, M., and Merten, O.W. (2010). Large-scale production means for the manufacturing of lentiviral vectors. Curr. Gene Ther. 10, 474-486.
34. Segura, M.M., Kamen, A., Trudel, P., et al. (2005). A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotech. Bioeng. 90, 391-404. (Pubitemid 40779190)
35. Segura, M.M., Kamen, A., and Garnier, A. (2006). Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol. Adv. 24, 321-337.
36. Slepushkin, V., Chang, N., Cohen, R., et al. (2003). Large-scale purification of a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange capsule. BioProcess. J. 2, 89-95.
37. Transfiguracion, J., Jaalouk, D.E., Ghani, K., et al. (2003). Sizeexclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther. 14, 1139-1153. (Pubitemid 36930404)
38. Xu, K., Ma, H., Mccown, T.J., et al. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104. (Pubitemid 32509810)
39. Zimmermann, K., Scheibe, O., Kocourek, A., et al. (2011). Highly efficient concentration of lenti-and retroviral vector preparations by membrane adsorbers and ultrafiltration. BMC Biotechnology 11, 55.